Table 3.
Multivariate Cox regression model of the association between stromal tumor-infiltrating lymphocytes (sTILs) in an interaction with treatment and recurrence-free survival (RFS) in clinically high-risk triple-negative patients
| Variable | n | adjusted hazard ratio | 95% CI | p value | |
|---|---|---|---|---|---|
| Treatment | ddAC | 49 | reference | ||
| TAC | 48 | 0.77 | 0.36–1.64 | 0.49 | |
| Age | <50 years | 49 | reference | ||
| ≥50 years | 48 | 1.07 | 0.50–2.30 | 0.85 | |
| T stage | T1 | 39 | reference | ||
| T2-4 | 58 | 1.29 | 0.60–2.77 | 0.51 | |
| N stage | N0 | 28 | reference | ||
| N+ | 69 | 14.16 | 1.91–105.0 | 0.009 | |
| Histologic grade | good/intermediate | 8 | reference | ||
| poor | 89 | 1.78 | 0.41–7.66 | 0.44 | |
| Type of surgery | breast-conserving surgery | 56 | reference | ||
| mastectomy | 41 | 0.87 | 0.41–1.87 | 0.72 | |
| sTILs | <20% | 40 | reference | ||
| ≥20% | 57 | 0.46 | 0.21–0.98 | 0.04 | |
| sTILs ∗ treatment | 0.14 | 0.03–0.74 | 0.02 |
Test for interaction between sTILs and treatment is shown in the last row. A, doxorubicin; C, cyclophosphamide; T, docetaxel; dd, dose-dense; sTILs, stromal tumor-infiltrating lymphocytes; CI, confidence interval.